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smooth muscle cell proliferation and extracellular matrix
accumulation.6,7
Another proteasome activator, PA700, primes the pro-
teasome to recognize and rapidly degrade ubiquitinated
substrates. Ubiquitin, an 8.6-kd protein, has been shown
to be involved in numerous intracellular processes, includ-
ing cell cycle control, apoptosis, regulation of transcrip-
tion, DNA repair, stress responses, and targeting cellular
proteins for degradation by the 26S proteasome.8 It is not
known whether the ubiquitin pathway and its integral
association with the proteasome contribute directly to the
process of AIH.
Defining the initial molecular events leading to AIH
after arterial grafting has been difficult secondary to lim-
ited graft-artery sample for analysis before cellular prolif-
eration. Furthermore, mRNA differential display and
other conventional molecular techniques require larger
volumes of tissue for analysis. Microarray technology
offers a new and highly sensitive method to assay gene
expression, requiring only 5 to 10 µg of specimen, and is
therefore better suited to determining the early molecular
events after arterial injury.
The goals of this study were twofold: (1) to identify
differential gene expression at 48 hours and 14 days after
arterial grafting and (2) to specifically evaluate whether
the proteasome/ubiquitin pathways were downregulated
in a similar fashion to that seen at later time intervals.
Defining the early molecular events after arterial grafting
Anastomotic intimal hyperplasia (AIH) remains a lead-
ing mechanism of delayed prosthetic arterial graft failure.
Previous studies have demonstrated hyperplastic lesions to
consist of early proliferation of vascular smooth muscle
cells followed by extracellular matrix elaboration and
deposition.1-5 Recent studies by this laboratory using mes-
senger RNA (mRNA) differential display to screen for
altered gene expression have identified several differen-
tially expressed genes in hyperplastic tissue compared with
control artery at delayed time intervals. Of note, the PA28
α subunit, a proteasome activator, was consistently under-
expressed in hyperplastic tissue. Downregulation of PA28
alters proteasome activation and function and may lead to
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Objective: Anastomotic intimal hyperplasia remains a leading mechanism of prosthetic arterial graft failure. Recent stud-
ies using messenger RNA differential display have demonstrated altered proteasome gene expression at the anastomoses
in an expanded polytetrafluoroethylene canine carotid model. However, this technique is technically limited because of
a paucity of available hyperplastic tissue at early time periods after arterial injury. Microarray gene chip technology offers
a new and sensitive technique to assay early gene expression, requiring far less tissue for analysis. The purpose of this
study was to screen for altered proteasome gene expression at 48 hours and 14 days after prosthetic arterial grafting.
Methods: Expanded polytetrafluoroethylene grafts (6-mm diameter, n = 9) were implanted into 25-kg mongrel dogs.
The normal intervening carotid artery was used as control. At 48 hours and 14 days, RNA was extracted from the peri-
anastomotic tissue and compared with RNA from the control carotid. Messenger RNA was then hybridized to microar-
ray genomes screening for differential gene expression.
Results: Two 26S proteasome genes and five ubiquitin pathway genes were significantly underexpressed at 48 hours,
among several hundred significantly expressed clones. The two 26S proteasome genes were 26S proteasomal subunit p55
(0.26), and 26S proteasomal subunit p40.5 (0.13). The underexpressed ubiquitin genes included ubiquitin (0.31), Nedd-
4-like ubiquitin-protein ligase (0.30), ubiquitin conjugating enzyme UbcH2 (0.25), putative ubiquitin C-terminal hydro-
lase UHX1 (0.11), and ubiquitin-conjugating enzyme UbcH7 (0.12). At 14 days, six ubiquitin genes were
underexpressed, and 17 26S proteasome genes were significantly downregulated.
Conclusions: This study shows decreased expression of the ubiquitin/proteasome pathway 48 hours after graft implan-
tation and similar diminished expression patterns after 14 days. This early and sustained underexpression after arterial
bypass may lead to altered cell cycle control and matrix protein signaling, contributing to the unregulated proliferation
of smooth muscle cells and extracellular matrix in anastomotic intimal hyperplasia after prosthetic arterial grafting.
(J Vasc Surg 2001;34:1016-22.)
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will identify the sequence of gene-related events leading to
AIH and may provide new targets for therapeutic inter-
vention.
METHODS
General materials. Mongrel dogs (25 kg) were
obtained, and care complied with the “Principles of
Laboratory Animal Care” formulated by the National
Society for Medical Research and the Guide for the Care
and Use of Laboratory Animals (NIH Publication No. 86-
23).9 Expanded polytetrafluoroethylene grafts were
obtained from W. L. Gore & Associates, Inc (Newark,
Del). The RNeasy Minikit was obtained from Qiagen, Inc
(Valencia, Calif). RNA Millennium Markers were obtained
from Ambion (Austin, Tex). Agarose was used from
Gibco-BRL Life Technologies (Rockville, Md). Micromax
microarray was obtained from New England Nuclear Life
Science Products (NEN) (Boston, Mass). A laser scanner
was used by NEN for microarray scanning from GSI
Lumonics (Kanata, Ontario, Canada). Affymetrix Human
Genome U95A gene chip array was used from Affymetrix
(Santa Clara, Calif).
Surgical graft placement. Expanded polytetrafluo-
roethylene grafts were surgically implanted into 25-kg
mongrel dogs. General anesthesia was established and
maintained using an initial sodium pentothal injection and
subsequent 1% halothane inhalation. Dogs designated for
48-hour analysis underwent bilateral graft implantation to
optimize the RNA yield with the intervening ipsilateral
carotid artery serving as the control (n = 6 grafts). The 14-
day dogs received unilateral grafts as there were sufficient
RNA yields with the additional postsurgical time with the
contralateral carotid artery serving as the control (n = 3).
A midline neck incision was made, and both carotid arter-
ies were dissected free from surrounding tissues, exposing
a 10-cm to 12-cm length segment. The animals were sys-
temically heparinized (100 U/kg), and the intervening
carotid artery segments were excised and snap frozen in
liquid nitrogen. These segments of normal artery served as
control tissue. All control segments were harvested before
any ischemia time. Expanded polytetrafluoroethylene
grafts were then implanted using standard tapered end-to-
end anastomoses with 6-0 prolene suture. At sacrifice,
grafts and 1 cm of anastomotic arterial segments were
excised. All grafts were patent at the time of harvest.
Longitudinal segments of the graft/artery interface (1.0 ×
0.3 × 0.2 cm) were excised for routine histologic analysis,
while the remainder of the tissue was immersed in liquid
nitrogen before RNA isolation.
RNA isolation. Graft artery interface tissue was pul-
verized in a cold mortar and pestle and ground in a Polytron
homogenizer (Kinematica AG, Lucerne, Switzerland). Total
RNA was then extracted using the RNeasy Minikit. RNA
purity and integrity were confirmed using RNA Millennium
Markers on an agarose gel with ethidium bromide staining.
Microarray screening. mRNA from control artery
and 48-hour arterial tissue was converted into biotin and
dinitrophenol complimentary DNA (cDNA), respectively,
using reverse transcriptase and nucleotide analogs. The
cDNA probes were then hybridized to the Micromax
microarray. This array contains 2400 human cDNA clones
from roughly 50 human cDNA libraries created by
Alphagene (Woburn, Mass). More than 10 tissue sources
are included in the array, with more than 40% full-length
genes. Biotin and dinitrophenol cDNAs were sequentially
detected using the tyramide signal amplification process,
in which two fluorescent reporter markers (cyanine 3 or
cyanine 5) were bound to the respective control or 48-
hour cDNA probes. Expression ratios were generated by a
laser scanner that measures the relative quantity of fluo-
rescent marker present on the hybridized probe.
Significant differential expression was determined as a
quantitative threefold difference in luminescence intensity
between control and 48-hour probes. Many microarray
protocols use a twofold difference as sufficient criteria for
detecting significant expression. By using a threefold dif-
ference for inclusion of altered expression, our threshold
for significant expression is more selective and likely rep-
resents a higher degree of sensitivity. Hybridization
integrity was additionally confirmed qualitatively via color
overlay analysis. RNA extracted from 14-day arterial tissue
was screened and compared with control artery using the
Affymetrix Human Genome U95A gene chip expression
Fig 1. Scatter plot analysis. This logarithmic graph depicts the
distribution of cyanine 3/cyanine 5 ratios of genes included in the
NEN microarray. Genes deviating from the diagonal axis denote
differential expression. The X axis depicts 48-hour artery expres-
sion. The Y axis represents control artery expression. Both expres-
sion levels are quantified measures of cyanine hapten fluorescence
intensity derived by the laser scanner and represent an average of
pixel intensities of each spot on the microarray.
JOURNAL OF VASCULAR SURGERY
1018 Stone et al December 2001
analysis probe array. Expression screening at 14 days used
the Affymetrix chip rather than the NEN microarray
because it incorporates significantly more genes, permit-
ting a broader expression profile with a greater number of
clones representing various portions of the ubiquitin and
proteasome systems. This gene chip is an oligonucleotide
array containing full-length genes representing 12,560
sequences characterized by function from the UniGene
database. In addition, the Affymetrix system is extremely
sensitive, detecting a single transcript in 100,000. Each
gene on the array is represented by several probe pairs.
Each probe pair contains perfect match and single mis-
match oligonucleotide sequences. A mismatch oligonu-
cleotide incorporates a homomismatch in the center base
location. The remainder is identical to the perfect match
sequence. The average intensity difference between the
perfect match and mismatch sequences depicts the expres-
sion level for a specific probe. The Affymetrix array also
incorporates reference sequences to serve as internal stan-
dards. Significant expression using this array represents
hybridization in both control and 14-day arteries with an
accompanying fold change >2, as recommended by the
manufacturer.
RESULTS
All grafts were patent at excision. Differential expres-
sion was first qualitatively evaluated via color overlay
analysis. Control artery tissue, bound with cyanine 5, was
represented by red shading. The forty-eight–hour artery,
labeled with cyanine 3, was depicted with green shading.
All signals detected from probes of both samples were
combined, creating a color overlay depicting differential
expression of the cDNA clones. Data were then assessed
graphically on a logarithmic scatter plot. All genes in the
microarray were plotted, representing a distribution of
cyanine 3 and cyanine 5 intensities. Deviation from the
diagonal axis depicts differential expression (Fig 1).
Finally, all data were correlated using a gene pie expression
plot. Pie size directly correlated with absolute intensity of
the probe, and red versus green coloration denoted differ-
ential expression of the specific clone. In this experiment,
cyanine-5–labeled control artery cDNA was depicted in
red and cyanine-3–tagged 48-hour artery cDNA was
shown in green.
Significant expression in the 48-hour samples was
determined to be a threefold difference in expression lev-
els between 48-hour artery and control artery. All numeric
expression levels represent a cyanine 3/cyanine 5 ratio.
Ratios depicting significant expression therefore were
greater than 3.0 or less than 0.33. Furthermore, genes
determined to be significantly differentially expressed were
consistent in a minimum of two segments of arterial tissue.
Of the three microarrays used to assess 48-hour arterial
tissue, each incorporated two segments of control artery
and two 48-hour perianastomotic tissue segments. In
total, six graft/artery segments and six control artery seg-
ments were analyzed. Significant expression in 14-day
arterial tissue was defined as a fold change >2 compared
with control artery.
Proteasome/ubiquitin related clones on the microar-
rays at 48 hours revealed significant diminished expression
of five ubiquitin pathway genes. In addition, two 26S pro-
teasome subunit genes were differentially underexpressed.
Among the ubiquitin pathway related genes, ubiquitin
(0.31), Nedd-4-like ubiquitin-protein ligase (0.30), 
ubiquitin-conjugating enzyme UbcH2 (0.25), Putative
ubiquitin C-terminal hydrolase UHX1 (0.11), and 
ubiquitin-conjugating enzyme UbcH2 (0.12) were all
demonstrated to be significantly downregulated in 48-
hour arterial tissue as compared with control. In addition,
mRNA for the 26S proteasome subunit p55 (0.26) and
26S proteasome subunit p40.5 (0.13) were significantly
underexpressed in the 48-hour arterial tissue (Table I).
The expression profile of the 14-day arterial tissue com-
pared with the control artery revealed a similar expression
pattern regarding proteasome and ubiquitin expression.
Fourteen days after prosthetic arterial bypass, six ubiquitin
pathway genes were underexpressed, and 17 26S protea-
some genes were significantly downregulated (Table II).
DISCUSSION
AIH remains a leading etiology for delayed prosthetic
vascular graft failure. This laboratory and others have
shown smooth muscle cell migration and proliferation fol-
lowed by extracellular matrix deposition as important
events leading to the formation of anastomotic lesions.1,3
The molecular events initiating these events after arterial
injury are not known. Furthermore, the effects of adding
Table I. Significant underexpression of ubiquitin/proteasome genes at 48 hours
Gene Ratio* Function
Ubiquitin 0.31 Targets protein to 26S proteasome
Nedd-4-ubiquitin protein ligase 0.3 E3 ubiquitin protein ligase
Ubiquitin conjugating enzyme UbcH2 0.25 E2 ubiquitin conjugating enzyme
Ubiquitin c-terminal hydrolase 0.11 E1 activating enzyme
Ubiquitin conjugating enzyme UbcH7 0.12 E2 ubiquitin conjugating enzyme
26S proteasome subunit p55 0.26 Proteasome subunit
26S proteasome subunit p40.5 0.13 Proteasome subunit
*Ratios depict cyanine 3:cyanine 5. Cyanine 3 is bound to 48-hour artery cDNA, and cyanine 5 is linked to control artery cDNA. All expression ratios
<0.33 represent significant expression differences as outlined in Methods.
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a prosthetic material may or may not augment the initial
response to vascular injury.
Previous work from our laboratory has shown that the
PA28 α subunit, a proteasome activator, was underex-
pressed at 90 days in hyperplastic artery compared with
control artery segments.6 This finding was the first to
identify the proteasome pathway as a potential regulator of
molecular events contributing to AIH. This initial finding
of a specific gene product being underexpressed in hyper-
plasia compared with control artery prompted further
experimentation at earlier time intervals after arterial graft-
ing.10 Early time intervals and their associated molecular
events after arterial bypass were initially problematic
because of an insufficient quantity of healed arterial tissue
for experimental analysis. Differential display and other
conventional molecular techniques require significant
quantities of tissue for evaluation. The development of
microarray gene chip technology offers a new and highly
sensitive method to assay differential gene expression with
a much smaller sample requirement. Microarray technol-
ogy is a part of the developing field of genomics. Earlier
techniques to evaluate gene expression were cumbersome,
time consuming, and costly. These techniques required
stringent laboratory environments free of RNase, suitable
probes for mRNA amplification, and random probes for
polymerase chain reaction–based amplification. cDNA
clones had to be back plotted onto Northern blots fol-
lowed by sequencing to determine altered gene expres-
sion. Microarrays offer a rapid screening protocol of
known genes. Thousands of genes of known sequence are
spotted onto microchips. In addition, mismatch base pairs
are added to ensure fidelity of complimentary pairing and
signal evaluation. In addition to microarray technology,
the amplification and detection of signal with flourescent
probes have greatly advanced the genomics field.
Following elimination of DNA from a test sample, the
RNA is isolated and the integrity confirmed on agarose
gel. Isolated mRNA or cDNA is labeled with fluo-
rochrome and exposed to the chip for complimentary
binding. This is a highly sensitive technique, allowing the
rapid screening of thousands of genes in a short period of
time. Furthermore, gene chip arrays require only 5 to 10
µg of specimen, making them a useful modality when lim-
ited material is available, as is the case in early time inter-
vals after vascular grafting.11 Furthermore, back screening
of Northern blots is not required, again sparing the need
for large quantities of mRNA. The ability to screen thou-
sands of genes in a single experimental procedure makes
microarray technology a useful genetic screening tool for
many vascular injury models. One issue unique to
microarray technologies is that chip content changes
quickly as new clones are found and added to the arrays.
PA28 is not the only proteasome activator. PA700, a
second proteasome activator, when bound to the protea-
some complex enables the recognition of ubiquitinated
proteins for degradation. The 26S proteasome serves as
the major nonlysosomal protease in eukaryotic cells for
targeting post-translational protein degradation.12 The
Fig 2. Diagram of ubiquitin and proteasome pathways. A protein is ubiquitinated and subsequently tar-
geted for degradation by the 26S proteasome. The PA700 activator recognizes and binds the polyubiqui-
tin tail. The protein is then digested in the proteasome core, releasing peptide fragments for further
processing. The ubiquitin residues are recycled for future protein binding. Ub, Ubiquitin.
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26S complex consists of two 700,000-dalton subunits, the
20S proteasome, and the associated PA700 activator com-
plex.13 The 26S proteasome complex is formed by the
association of PA700 adenosine triphosphatase caps to the
ends of the 20S barrel core.14,15
Ubiquitin, originally thought to be a thymic hor-
mone, was first isolated from the thymus by Goldstein et
al in 1975.16,17 It derives its name from the fact that its
conjugates are present in all eukaryotic cells.18 Ubiquitin
is a highly conserved 8.6-kd protein that serves as a cova-
lent marker for nonlysosomal protein degradation by the
26S proteasome.19 Proteins are targeted for breakdown by
the proteasome via the complex binding of ubiquitin
residues. Often, additional ubiquitin residues are then
added to a monoubiquitinated substrate, forming long
polyubiquitin tails. The PA700 ATPase activator compo-
nent of the 26S proteasome is then capable of polyubiqui-
tin tail recognition and subsequent binding. Once bound,
PA700 unfolds complex protein topology, rendering it sus-
ceptible to degradation through contact with hydrolytic
sites within the proteasome core.20 The proteasome then
degrades the target protein, releasing small peptides and
ubiquitin residues (Fig 2).21 The central role of the pro-
teasome/ubiquitin pathway in intracellular homeostasis
has only recently been appreciated. The ubiquitin pathway
has been shown to be involved in cell cycle regulation,
receptor function, apoptosis, regulation of transcription,
DNA repair, and intracellular signaling pathways.8 Before
this study, the underexpression of the ubiquitin/protea-
some gene related pathways had not been described in
intimal hyperplasia.
The current study documents that ubiquitin and sev-
eral associated enzymes are significantly underexpressed at
both 48 hours and 14 days after prosthetic arterial bypass
grafting. Specifically, members of both the E2 conjugating
enzyme and E3 ligase families were downregulated (Table
I). The same data set reveals that two distinct subunits of
the 26S proteasome are underexpressed at 48 hours as
well. Similar underexpression was observed in the protea-
some system at 14 days (Table II). These findings, in con-
junction with our laboratory’s previous work, indicate that
altered expression of the ubiquitin/proteasome system is
an early and sustained molecular response following pros-
thetic arterial grafting.
Protein-ubiquitin ligation is regulated by several
enzymes, which ultimately catalyze the polyubiquitinated
moiety for proteasome degradation. A ubiquitin activating
enzyme, E1, activates the c-terminal glycine of ubiquitin
in an ATP dependent process. A ubiquitin conjugating
enzyme, E2, accepts the activated substrate and transfers it
to a protein moiety in the presence of a ubiquitin-protein
ligase. The ubiquitin-protein ligase, E3, catalyzes the for-
mation of an isopeptide bond between the activated c-ter-
minal glycine of ubiquitin and the lysine residue amino
group on the target protein.16 Currently, there are at least
20 known E2 conjugating proteins in mammals and
approximately 12 known E3 ubiquitin ligases.21,22 The
ubiquitination process is therefore inherently complex
with its multiple permutations of E1, E2, and E3 moieties
expressed at specific intracellular locations and time
points.21
Other investigators have shown in nonarterial models
that the ubiquitin and proteasome pathways play a pivotal
role in governing intracellular protein degradation.
Through their ability to regulate transcription, apoptosis,
intracellular signaling, and protein degradation, decreased
expression of the ubiquitin/proteasome pathway after arte-
rial bypass may alter cell cycle control via decreased degra-
dation of stimulatory cytokines and regulatory proteins
such as cyclin-dependent kinases, E2F, c-myc, c-jun, c-fos,
p27, p57, and p53.23 The net effect of these changes
would be to have sustained early cellular proliferation in
excess of normal growth control regulation by the protea-
some pathway. Furthermore, decreased clearance by the
proteasome of intracellular signals regulating extracellular
matrix production might lead to unregulated extracellular
matrix deposition, contributing to the anastomotic steno-
sis. Continued investigation of altered gene expression at
additional time intervals after arterial grafting will further
clarify the molecular events leading to AIH formation.
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Dr Anton N. Sidawy (Washington, DC). I rise to congratu-
late the authors, the Beth Israel Deaconess group, for this very
important contribution to our knowledge of the pathogenesis of
intimal hyperplasia.
Cellular signaling pathways leading to the development of
vascular disease continue to gain much clinical interest. Just to
recap a little, ubiquitination is a primary mechanism by which
proteins are targeted for degradation, and, depending on its sub-
strate, can influence cell proliferation or its demise (apoptosis).
Ubiquitin is a 76 amino acid polypeptide that’s covalently bound
to a substrate in three key enzymatic steps—activation, conjuga-
tion, and ligation.
Polyubiquitination of cytoplasmic proteins have been
observed in macrophages, cultured in LDL, which upregulates a
ubiquitin conjugating enzyme. Kakuchi and colleagues demon-
strated that proteasome-directed degradation of P53 suppressed
apoptosis and promoted macrophage transformation to foam
cells, an initial step in the formation of the atherosclerotic lesion.
So folks, this stuff is really important.
I submit the following questions to the authors.
Did you perform any technique to histologically correlate
with the formation of intimal hyperplasia? Did you measure inti-
mal hyperplasia to correlate it with your findings?
Could this simply represent a transient activation of prosur-
vival pathway in tissues exposed to an acute injury or inflamma-
tory event?
How does this underexpression contribute to the pathogen-
esis of intimal hyperplasia?
Did you consider western blotting or PCR techniques to
complement your gene chip array analysis?
And finally, what ultimately determines whether a protein will
become ubiquitinated or not?
Thank you very much.
Dr David H. Stone. Thank you, Dr Sidawy, for your com-
ments and questions.
In regard to performing routine histology at the time of graft
anastomotic artery explantation, a small segment was excised and
embedded in paraffin and then analyzed to confirm the presence
of a histologic lesion and therefore ensure the fact that we were
actually extracting and analyzing RNA from an intimal hyperplas-
tic lesion.
Could this be a transient activation of a prosurvival pathway?
That is possible. The initial inflammatory response to the arterial
injury may activate many of the cellular responses to arterial
injury. But I think the fact that our data show sustained decreased
expression of these pathways implicates that there is more than
just a transient activation of a prosurvival pathway.
In regard to how the underexpression of these pathways leads
to intimal hyperplasia, we believe that the lesion in intimal hyper-
plasia has been characterized to consist of proliferating vascular
smooth muscle cells, which are then elaborated by the deposition
of extracellular matrix.
Towards the end of the talk I tried to explain that the
cytokines involved with cell cycle control proteins are released fol-
lowing arterial injury. If the ubiquitin and proteasome pathways
are unable to degrade these proteins in a regulated fashion, there
may be varying degrees of longevity for these proteins which may,
therefore, alter cell cycle control and lead to the unregulated pro-
liferation of the vascular smooth muscle cells.
In addition to our microarray data, investigators in the past
have used PCR, Western blotting, or Northern blot confirmation.
So far we have not done any type of additional conventional mol-
ecular techniques to confirm our microarray data. Currently I
think it’s still controversial as to whether or not this fully needs to
be done. However, if there were a specific gene in question that
were going to be analyzed in more detail in the future, it would
DISCUSSION
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probably behoove the investigator to confirm it in a more quan-
tifiable fashion.
And the advantage, of course, of the microarray, is that
whereas with conventional molecular techniques you’re limited to
assessing the expression of one, maybe two genes, this permitted
us to look at the expression of 12,000 genes with only 5 to 10 µg
of RNA. Obviously to look at a lesion 48 hours postoperatively,
there isn’t sufficient cellular proliferation and therefore enough
tissue to perform some of these conventional techniques.
Dr K. Craig Kent (New York, NY). Congratulations on mas-
tering this technique. Your group was one of the first to use
arrays, and you have continued your excellent work.
There are now many groups using microarray to look at inti-
mal hyperplasia. A number of different models have been evalu-
ated, including a carotid injury model, a vein graft model,
different animals, human tissue…
How do your results compare to the findings of these other
studies? Is the pattern of gene expression uniform regardless of
the animals and/or the model?
You have found many different genes that are turned on and
off. But what you need to do now is determine cause and effect.
How will you prove that upregulation of ubiquitin and the pro-
teasomes causes intimal hyperplasia?
The last question has to do with the microarray technique.
You use two different microarray panels. Why didn’t you use the
one that looks at the greater number of genes for all of your
experiments?
Excellent work which I very much enjoyed.
Dr Stone. To address your last question first, the reason we
switched to the Affymetrix chip, which does contain significantly
more genes, was because, as we were performing the experiment
over several months, the technology was changing over the same
duration. When we initially analyzed the 48-hour tissue, the
Affymetrix chip with 12,000 genes wasn’t available to us. We
thought that rather than repeat the experiment with a more
defunct chip, it would be more interesting to screen for an
increased number of genes.
As to the cause and effect, taking the microarray data alone
doesn’t conclude much. However, our findings of these two path-
ways that are uniformly underexpressed confirm differential dis-
play and Northern blot confirmation conducted in our labora-
tory, which documented that PA28, proteasome activator, was
underexpressed. When we performed the microarray screening,
which possesses many proteasome genes, the fact that we saw uni-
form underexpression validated our previous finding. Clearly, I
think more work needs to be done and possibly in an in vivo
model, too, using now readily available proteasome inhibitors in
that capacity.
And specifically how our results compare to other groups
using microarrays for other vascular pathologic processes, I can’t
really comment specifically. One of the limiting factors, of course,
is you get back a CD-ROM with thousands and thousands of
genes, some upregulated, some underexpressed, and it is up to
the investigator to pick a focus of what to explore. I could find,
I’m sure, many other interesting areas that were overexpressed or
underexpressed.
Dr Alan Dardik (Baltimore, Md). I congratulate you on that
very interesting and provocative work. I only ask simply have you
looked at any other models of intimal hyperplasia with the same
experimental technique? Is this simply a result of your model or is
this present in all models of intimal hyperplasia?
Dr Stone. In terms of which species of animal to use?
Dr Dardik. Yes, different species, different types of contrast.
Dr Stone. We typically have used a canine model because dogs
heal in a similar capacity to humans. Dogs, like humans, have the
inability to endothelialize a graft. And we maintain that the dog
is the best animal model to mimic human intimal hyperplasia. 
Dr Jason M. Johanning (Danville, Pa). What effect does
using a dog model have on human-specific gene arrays?
Dr Stone. That’s an excellent point and probably one of the
limiting factors of the study. As I mentioned, we use the canine
model because they heal most similarly to humans. Though these
are human genes on the array, there is overlap. And as I men-
tioned in the talk, ubiquitin is conserved among species. So we
feel rather comfortable that at least the genes from the ubiquitin
pathway are real. Whether or not there is 100% overlap is unclear;
however, it obviously would be much better to use human tissue
on this array.
